CMS is holding off on its voluntary “Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth” model pilot for Medicare Part D, the agency confirmed to Becker’s April 21. Under BALANCE, CMS would negotiate lower GLP-1 prices for Medicaid programs…
GLP-1s
More Wegovy prescriptions are being written as GLP-1 weight loss drugs gain traction across retail, telehealth and direct-to-consumer channels, according to an April 20 report from Truveta Research. The growth follows the FDA’s December approval of oral Wegovy (semaglutide) and…
Researchers at the University of Pennsylvania in Philadelphia have used AI to analyze more than 400,000 Reddit posts and identify potential GLP-1 side effects not fully captured in clinical trials. The analysis included posts from nearly 70,000 users discussing drugs…
Walmart has expanded its Better Care Services platform to include weight management support for customers using or considering GLP-1 therapies, including access to medications such as Foundayo (orforglipron). Walmart said the platform integrates virtual care, nutrition services and pharmacy access…
The FDA is requiring Eli Lilly to conduct extensive postmarketing studies for its newly approved GLP-1 pill Foundayo (orforglipron) to further assess potential safety risks. The agency said additional data is needed to evaluate risks, including major adverse cardiovascular events,…
Advertisement
Use of GLP-1 receptor agonists continues to shift rapidly, with early April developments highlighting changes in pricing models, drug access, regulatory oversight and personalized care. Here are five notable GLP-1 developments: 1. Pricing models diversify to boost access Novo Nordisk…
The world’s two main GLP-1 drug manufacturers, Eli Lilly and Novo Nordisk, are taking different approaches with rolling out their recently approved GLP-1 pills for weight loss. Two oral GLP-1s, two very different commercial strategies. Health systems operating metabolic programs…
Researchers at the 23andMe Research Institute have identified genetic variants linked to weight loss and side effects among patients using GLP-1 receptor agonists. The study, published April 8 in Nature, analyzed data from 27,885 people who reported using GLP-1 medications.…
Amazon Pharmacy has begun offering Eli Lilly’s GLP-1 medication, Foundayo, via same-day delivery. The once-daily oral treatment is approved for adults with obesity or overweight with weight-related conditions. Patients with a valid prescription can order the drug with real-time pricing…
Novo Nordisk’s recently approved high-dose Wegovy formulation has entered the U.S. market and is available for $399 per month for self-paying patients, the drugmaker said April 7. In March, the FDA approved Wegovy HD, a 7.2-mg injection of semaglutide, as…